Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Point72 Asset Management

Major Wall Street firms targeted in attempted cyberattacks, sources say

Major Wall Street financial firms faced sophisticated cyberattacks recently. Hackers used phone calls to trick employees into granting access. Several large hedge funds and private equity firms were targeted by these attempts. Point72 Asset Management confirmed an attack but stated no customer data was stolen. Global companies are now battling…

The Economic Times

Steve Cohen's Point72 Buys $20M of Biotech Stock Advancing Depression Treatment

Steve Cohen's Point72 Buys $20M of Biotech Stock Advancing Depression Treatment

Point72 Asset Management purchased over 1.2 million shares of Tonix Pharma at $16.28 each as the company aggressively advances its drug development programmes.

International Business Times UK

Steve Cohen's Point72 Buys $20M of Surging Biotech Stock That Recently Priced $125M Offering to Advance Myeloma Treatment

Steve Cohen's Point72 Buys $20M of Surging Biotech Stock That Recently Priced $125M Offering to Advance Myeloma Treatment

Cohen's Point72 purchased over 8 million shares of C4 Therapeutics within weeks of the company announcing phase 1 trial data of a drug to treat myeloma and raised $125 million to fund upcoming trials.

International Business Times UK

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Steven Cohen Doubles The S&P 500 — And His Next Bet's All Gut

Steven Cohen's Point72 Asset Management just pulled off what most fund managers only dream of — doubling the SP 500's three-year return — and he's still not easing up. The billionaire investor's next move? A fresh swing into biotech, backing Palisade Bio Inc (NASDAQ:PALI) — a tiny, high-volatility stock working…

Steven Cohen's Biotech Bets Are Getting Bolder — And Smaller

Steven Cohen isn't afraid of volatility — and his latest moves show he's diving headfirst into small-cap biotech. The billionaire hedge fund manager's Point72 Asset Management has built new stakes in two clinical-stage companies, betting that their breakthroughs in genetic and antibody therapies could deliver outsized returns.

Steve Cohen's Point72 Goes Heavy on Tech and Pharma Stocks, Investing Over $330M in Two Trades

Point72 Asset Management recently purchased over 10 million shares of Confluent and Amylyx Pharma common stock, worth more than $334.17 million.

International Business Times UK

Point72's Steve Cohen Adds $2B Worth of New Tech, Telco, and Healthcare Stocks in Q4

Billionaire investor Steven A. Cohen opened new stock positions, including Amazon, AT&T, Netflix, Salesforce, and UnitedHealth Group in Q4.

International Business Times UK

inkl

Read news from The Economist, FT, and more,
with one subscription

Steve Cohen's Point72 Ups Stake in Boeing by Over 400% in Q1, Opens New Position in Broadcom

Steve Cohen's Point72 Ups Stake in Boeing by Over 400% in Q1, Opens New Position in Broadcom

Boeing has trimmed delivery and production of its 737 Max fleet, while Broadcom's quarterly revenue jumped 34% YoY on high chip demand for AI data centres.

International Business Times UK

Hedge fund billionaire Steve Cohen says focusing too much on a looming recession could make you miss the 'big wave' of A.I. opportunity. 'I'm actually pretty bullish.'

Hedge fund billionaire Steve Cohen says focusing too much on a looming recession could make you miss the 'big wave' of A.I. opportunity. 'I'm actually pretty bullish.'

“I’m making a prognostication—we’re going up,” the billionaire investor said at a private event Tuesday, Bloomberg first reported, citing unnamed sources.

Why Minerva Neurosciences Shares Traded Higher By Over 66%; Here Are 78 Biggest Movers From Yesterday

Why Minerva Neurosciences Shares Traded Higher By Over 66%; Here Are 78 Biggest Movers From Yesterday

Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) shares gained 66.5% to close at $7.51 after Point72 Asset Management reported an 8.8% passive stake in the company.

Here's A Dividend Stock Both Warren Buffett And George Soros Agree On

Here's A Dividend Stock Both Warren Buffett And George Soros Agree On

After tirelessly analyzing Warren Buffett, George Soros and Steven Cohen’s 13F SEC filings for the second quarter of 2022, we've gained a better understanding of the investment strategies they've adopted and the construction of their hedge funds portfolios.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

UnitedHealth Group

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Social Security

Places

404,582 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play